Log In
Print this Print this

AVP-21D9 (formerly AVP 21D9)

  Manage Alerts
Collapse Summary General Information
Company Emergent BioSolutions Inc.
DescriptionHuman mAb against Bacillus anthracis protective antigen
Molecular Target Bacillus anthracis protective antigen
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAnthrax
Indication DetailsVaccinate against Bacillus anthracis (anthrax)
Regulatory Designation U.S. - Fast Track (Vaccinate against Bacillus anthracis (anthrax));
U.S. - Orphan Drug (Vaccinate against Bacillus anthracis (anthrax))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today